Webinar :Register now for webinar on 'Trade BankNifty in just 15 minutes a day' - By Asmita Patel
Last Updated : Jul 08, 2020 09:07 PM IST | Source: PTI

With an eye on economic growth, Nirmala Sitharaman meets CMDs of 23 PSUs to discuss capex plans

The meeting was held as part of the series of meetings that the finance minister is having with various stakeholders to accelerate economic growth.

PTI

Finance Minister Nirmala Sitharaman on July 7 met with chiefs of 23 state-run banks and stressed the need for timely capital expenditure (capex) to provide a fillip to economic growth. For FY21, the consolidated capex target of these 23 Central Public Sector Enterprises (CPSEs) is Rs 165,510 crore.

"Finance Minister Smt. @nsitharaman held meeting through VC with Secretaries and CMDs of 23 CPSEs of @PetroleumMin , @MinOfPower , @CoalMinistry, @MinesMinIndia and Dept. of Atomic Energy, to review capital expenditure in this financial year," the finance ministry tweeted.

The meeting was held as part of the series of meetings that the finance minister is having with various stakeholders to accelerate economic growth.

Close

During the meeting, the finance minister emphasised on timely capex by the CPSEs to give a boost to economic growth of the country, it said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
"Encouraging CPSEs to perform better with timely achievement of targets, Finance Minister Smt.@nsitharaman said that better performance of CPSEs can help the economy in a big way to recover from the impact of #COVID19," the ministry said.
First Published on Jul 7, 2020 07:48 pm
Sections